KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.95

Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial).

Yuki Imai, Michihito Kono, Tomonori Ishii, Toshihisa Kojima, Shintaro Hirata, Yoshiya Tanaka, Eiichi Tanaka, Koichiro Ohmura, Shunsuke Okamoto, Rumiko Matsumoto, Yuri Sato, Takashi Yamamura, Tsutomu Takeuchi, Yuko Kaneko

Ann Rheum Dis 85(4) 609-619

PMID41763966
PMCID-
DOI10.1016/j.ard.2026.02.004
发表日期2026-02-28
入排依据:The study is a randomized Phase III trial of a TNF inhibitor (ozoralizumab) for rheumatoid arthritis. It is not an oncology study. The primary endpoint is a categorical outcome (proportion maintaining low disease activity), not a time-to-event endpoint (e.g., OS, PFS, DFS, etc.) with Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the eligibility criteria for this oncology Kaplan-Meier digitization cohort.
入排复审未纳入:The study is a randomized Phase III trial of a TNF inhibitor (ozoralizumab) for rheumatoid arthritis. It is not an oncology study. The primary endpoint is a categorical outcome (proportion maintaining low disease activity), not a time-to-event endpoint (e.g., OS, PFS, DFS, etc.) with Kaplan-Meier or hazard ratio analysis. Therefore, it does not meet the eligibility criteria for this oncology Kaplan-Meier digitization cohort.
摘要

摘要

OBJECTIVES: This study aimed to assess the noninferiority of spacing a tumour necrosis factor (TNF) inhibitor or reducing the methotrexate dose with continued treatment in patients with rheumatoid arthritis. METHODS: The SORAIRO trial was a multicentre, open-label, randomised, noninferiority study. Patients who had been in remission or low disease activity based on the Clinical Disease Activity Index (CDAI) in the preceding phase III trial of ozoralizumab, a next-generation TNF inhibitor, were enrolled. The precalculated sample size was 141. Patients were randomised into continued treatment, ozoralizumab spacing, or methotrexate dose reduction groups. The primary endpoint was a noninferiority of low disease activity maintenance at week 48 with a prespecified noninferiority margin of -18%. RESULTS: A total of 144 patients were analysed. The mean age was 58.2 years, 75.0% were female, and the mean CDAI was 2.70 with 61.8% in remission. The low disease activity at week 48 was 97.9% in the continued treatment group, 79.2% in the ozoralizumab spacing group (difference, -21.6; 95% CI, -39.9 to -5.7), and 72.7% in the methotrexate dose reduction group (difference, -30.4; 95% CI, -54.0 to -10.5). In the baseline remission subgroup, remission maintenance rates were comparable in the 3 groups (77.4%, 76.7%, 79.2%, respectively). No significant differences were demonstrated in changes in the Health Assessment Questionnaire Disability Index and modified total Sharp score. Adverse events occurred in 68.0%, 59.2%, and 58.0%, respectively. CONCLUSIONS: Treatment tapering may not be feasible in patients with low disease activity, whereas both extending the TNF inhibitor interval and reducing the methotrexate dose may be reasonable options for patients in remission.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。